Elevance Health Inc. (ELV) reported earnings on April 20, 2026, with the market responding positively to the results. The healthcare benefits company, which serves approximately 118 million people through medical, digital, pharmacy, and behavioral solutions, saw its stock rise 2.8% following the announcement. With a market cap of $70.45 billion and a Meyka AI grade of B+, Elevance Health continues to demonstrate solid operational performance in the competitive medical-healthcare plans sector. The company’s latest earnings results provide important insights into its financial trajectory and market positioning.
Elevance Health Earnings Results Overview
Elevance Health released its latest earnings report on April 20, 2026, marking another quarter of performance for the healthcare giant. The company’s stock responded favorably, climbing 2.8% on the day as investors digested the financial results. This positive market reaction reflects confidence in the company’s operational execution and financial health.
Stock Price Movement and Market Response
The stock gained $8.96 per share, closing at $328.33 on strong trading volume. The company’s 52-week range spans from $273.71 to $432.93, placing current valuations near the middle of that range. Trading volume reached 1.78 million shares, slightly below the 1.98 million average, suggesting measured investor interest rather than panic buying or selling.
Valuation Metrics and Investor Positioning
Elevance Health trades at a P/E ratio of 13.02, well below the broader market average. The stock’s price-to-sales ratio of 0.35 indicates attractive valuation relative to revenue generation. With 220.7 million shares outstanding, the company maintains a solid equity base supporting its $70.45 billion market capitalization.
Financial Performance Compared to Previous Quarters
Examining Elevance Health’s recent earnings history reveals consistent operational performance with some notable trends. The company has demonstrated resilience across multiple quarters, though recent results show mixed momentum in key metrics.
Recent Quarter Performance Trends
In the most recent comparable quarter (Q1 2026, ended January 30), Elevance Health reported EPS of $3.33, beating the estimate of $3.10 by 7.4%. Revenue came in at $49.31 billion, missing the estimate of $49.84 billion by 1.1%. This pattern of beating earnings while slightly missing revenue suggests strong cost management and operational efficiency despite top-line pressures.
Year-Over-Year Comparison
Looking back to Q3 2025 (ended October 17), the company reported EPS of $8.84 against an estimate of $8.91, representing a 0.8% miss. Revenue of $49.78 billion beat the estimate of $48.19 billion by 3.3%. The company’s ability to generate strong revenue growth while managing earnings demonstrates its pricing power and operational leverage in the healthcare benefits market.
Earnings Consistency and Reliability
Across the last four quarters, Elevance Health has maintained relatively stable earnings performance with an average EPS of approximately $8.02. The company’s net profit margin of 2.84% reflects the capital-intensive nature of healthcare benefits operations. Operating margins of 4.07% show the company’s ability to control costs while managing complex healthcare networks.
Key Financial Metrics and Operational Strength
Elevance Health’s financial foundation demonstrates the company’s ability to generate consistent cash flows and maintain shareholder returns. The healthcare benefits provider shows solid operational metrics that support its market position.
Cash Flow Generation and Capital Allocation
The company generated $19.34 per share in operating cash flow on a trailing-twelve-month basis. Free cash flow reached $14.31 per share, representing a 74% conversion rate from operating cash flow. This strong cash generation supports the company’s $3.43 dividend per share, yielding approximately 1.08% annually. The payout ratio of 27% leaves substantial room for reinvestment and share buybacks.
Balance Sheet and Leverage Profile
Elevance Health maintains a debt-to-equity ratio of 0.76, indicating moderate leverage appropriate for a healthcare benefits company. The current ratio of 1.24 demonstrates adequate liquidity to meet short-term obligations. Interest coverage of 5.79x shows the company comfortably services its debt obligations from operating earnings.
Return Metrics and Profitability
The company delivered a return on equity of 13.01% and return on assets of 4.66%, both solid for the healthcare sector. Book value per share stands at $198.49, supporting the stock’s valuation. The company’s EPS of $25.20 on a trailing basis reflects the cumulative earnings power across all business segments.
Market Outlook and Meyka AI Assessment
Elevance Health’s positioning in the healthcare benefits market remains strong despite industry headwinds. The company’s recent performance and forward indicators suggest continued operational stability with selective growth opportunities.
Meyka AI Grade and Investment Perspective
Meyka AI rates ELV with a grade of B+, reflecting solid fundamental strength and market positioning. The grade incorporates multiple factors including financial growth metrics, key valuation ratios, analyst consensus, and sector comparisons. This rating suggests the stock offers reasonable value for investors seeking healthcare sector exposure with established market presence.
Analyst Consensus and Price Targets
Wall Street maintains a constructive stance on Elevance Health, with 15 buy ratings and 4 hold ratings from major analysts. No sell ratings exist, indicating broad confidence in the company’s strategic direction. The consensus recommendation translates to a buy rating with a score of 3.00 on a 5-point scale.
Forward Growth Expectations
The company’s revenue growth of 12.6% year-over-year demonstrates strong top-line expansion. However, net income declined 5.3% in the most recent period, reflecting margin pressures from medical cost inflation and competitive dynamics. The company’s ability to navigate these pressures while maintaining profitability will be critical for future performance.
Final Thoughts
Elevance Health’s April 2026 earnings release demonstrated the company’s continued operational competence in a challenging healthcare environment. While specific EPS and revenue figures for the latest quarter remain preliminary, the stock’s 2.8% gain reflects investor confidence in management’s execution. The company’s solid cash generation, moderate leverage, and consistent dividend support position it well for long-term shareholders. With a Meyka AI grade of B+ and analyst consensus favoring accumulation, Elevance Health appears well-positioned to navigate industry headwinds while delivering shareholder value through a combination of earnings growth and capital returns.
FAQs
How did Elevance Health’s stock perform after earnings?
ELV stock rose 2.8% following earnings, gaining $8.96 per share to close at $328.33. Trading volume of 1.78 million shares indicated moderate investor interest in the positive results.
What is Meyka AI’s rating for Elevance Health?
Meyka AI assigns ELV a B+ grade, reflecting solid fundamental strength based on financial growth, valuation metrics, analyst consensus, and sector comparisons.
How does ELV’s valuation compare to the market?
ELV trades at a P/E of 13.02 and price-to-sales of 0.35, both below market averages, suggesting reasonable value relative to earnings and revenue.
What is Elevance Health’s dividend yield?
ELV pays a $3.43 annual dividend with a 1.08% yield. The 27% payout ratio allows room for future increases while maintaining capital for reinvestment and buybacks.
How strong is Elevance Health’s cash flow?
ELV generated $19.34 per share in operating cash flow and $14.31 in free cash flow on a trailing basis, supporting dividends and providing financial flexibility.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Earnings estimates are analyst projections and not guarantees of actual results. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)